OpportunityTitle: Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21)
AdditionalInformationOnEligibility: Other Eligible Applicants include the following:   Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Description: Purpose. The purpose of this Funding Opportunity Announcement (FOA) is to support innovative exploratory/developmental investigations in primary immunodeficiency diseases focusing on ex vivo studies with human specimens and on studies with current or new animal models, including novel clinical strategies for detecting, identifying the molecular basis of, or developing innovative therapies for, primary immunodeficiency diseases. Investigators who have no prior history of receiving independent NIH funding or no prior history of receiving independent NIH funding in this field are encouraged to apply to this FOA. Mechanism of Support. This FOA will use the NIH Exploratory/Developmental (R21) award mechanism and runs in parallel with a FOA of identical scientific scope, PA-10-147, that encourages applications under the R03 small grant mechanism. Funds Available and Anticipated Number of Awards. It is anticipated that approximately $650,000 will be available under this FOA and that 2 new awards will be made each fiscal year. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.
GrantorContactEmailDescription: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
GrantorContactText: NIH OER Webmaster &lt;br/&gt;FBOWebmaster@OD.NIH.GOV &lt;br/&gt;